Literature DB >> 1563093

Status of immune-based therapies in HIV infection and AIDS.

J L Fahey1, R Schooley.   

Abstract

As our understanding of HIV disease pathogenesis progresses, approaches to immune-based therapy are evolving. Initial therapies aiming to alter immune function in patients with HIV infection have had mixed results. Clinical benefit in the trials so far has not been dramatic, although the studies are still at an early stage, and the correct protocols for the various agents or combinations of agents have yet to be established. As might be expected, where apparent benefit has occurred, it has been more obvious in those patients whose immune system was still intact.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1563093      PMCID: PMC1554384          DOI: 10.1111/j.1365-2249.1992.tb03029.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  11 in total

1.  Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.

Authors:  A Weinberg; T C Merigan
Journal:  J Immunol       Date:  1988-01-01       Impact factor: 5.422

2.  Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections.

Authors:  S A Miles; H J Wang; E Cortes; J Carden; S Marcus; R T Mitsuyasu
Journal:  Ann Intern Med       Date:  1990-04-15       Impact factor: 25.391

Review 3.  NIH conference. Development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection.

Authors:  A S Fauci; R C Gallo; S Koenig; J Salk; R H Purcell
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

4.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus.

Authors:  D H Schwartz; G Skowron; T C Merigan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

6.  A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.

Authors:  R R Redfield; D L Birx; N Ketter; E Tramont; V Polonis; C Davis; J F Brundage; G Smith; S Johnson; A Fowler
Journal:  N Engl J Med       Date:  1991-06-13       Impact factor: 91.245

7.  Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)

Authors:  J A Kovacs; L Deyton; R Davey; J Falloon; K Zunich; D Lee; J A Metcalf; J W Bigley; L A Sawyer; K C Zoon
Journal:  Ann Intern Med       Date:  1989-08-15       Impact factor: 25.391

8.  Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)

Authors:  S E Krown; J W Gold; D Niedzwiecki; D Bundow; N Flomenberg; B Gansbacher; B J Brew
Journal:  Ann Intern Med       Date:  1990-06-01       Impact factor: 25.391

9.  Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.

Authors:  H C Lane; V Davey; J A Kovacs; J Feinberg; J A Metcalf; B Herpin; R Walker; L Deyton; R T Davey; J Falloon
Journal:  Ann Intern Med       Date:  1990-06-01       Impact factor: 25.391

10.  Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.

Authors:  R T Schooley; T C Merigan; P Gaut; M S Hirsch; M Holodniy; T Flynn; S Liu; R E Byington; S Henochowicz; E Gubish
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

View more
  3 in total

1.  Selection of a muramyl peptide based on its lack of activation of nuclear factor-kappa B as a potential adjuvant for AIDS vaccines.

Authors:  R Schreck; D Bevec; P Dukor; P A Baeuerle; L Chedid; G M Bahr
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  Anti-IL-4 monoclonal antibody and IFN-gamma administration retards development of immune dysfunction and cytokine dysregulation during murine AIDS.

Authors:  Y Wang; S K Ardestani; B Liang; C Beckham; R R Watson
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

3.  Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.

Authors:  H Zaghouani; S A Anderson; K E Sperber; C Daian; R C Kennedy; L Mayer; C A Bona
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.